Research programme: anticancer antibodies - Medarex/Prima BiomedAlternative Names: Cripto-1 antibody
Latest Information Update: 16 Jul 2016
At a glance
- Originator Medarex; Prima Biomed
- Developer Prima BioMed
- Mechanism of Action Endothelial growth factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 06 Jul 2011 Preclinical trials in Cancer in Australia (Parenteral)
- 03 May 2007 Discontinued - Preclinical for Cancer in Australia (unspecified route)